Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
USA
International
Our purpose
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies.
Our credentials
Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016. With additional operations in the Netherlands and the USA, we continue to grow our global team.
To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing.
- Listing on the SIX Swiss Exchange under the symbol KURN
- A commercial & research footprint that spans >20 markets
- 4 teams of internationally renowned clinical and scientific expert advisers
- >25 orthobiologics-related patents
- >400 patients evaluated in Level I, randomized controlled clinical trials
- 10 well-controlled Level I-III clinical trials initiated, including 6 that are complete*
- Published Level 1 evidence in Spine
Conferences
Meet the Kuros team at our next conference and discover how our groundbreaking technology is transforming the future of bone healing. Don’t miss this chance to connect, learn, and be inspired!
16 Jan 2025
American Orthopaedic Foot & Ankle Society (AOFAS)
Lake Louise, Alberta, Canada
19 Jan 2025
Base to Summit
Vail, CO
29 Jan 2025
Selby Spine
Deer Valley, UT
20 Feb 2025
Spine Summit
Tampa, FL
25 Mar 2025
American College of Foot and Ankle Surgeons (ACFAS)
Phoenix, AZ
26 Jun 2025
State of Spine Surgery Think Tank
San José del Cabo, Mexico
02 Oct 2025
Society for Minimally Invasive Spine Surgery (SMISS)
Las Vegas, NV
22 Oct 2025
Eurospine
Copenhagen, Denmark
14 Nov 2025
North American Spine Society (NASS)
Denver, CO
23 Nov 2025
Spine IEP
Location TBD
03 Dec 2025
Cervical Spine Research Society (CSRS)
Washington, DC
Our Story
November 2024
Kuros Biosciences expands into extremities markets
October 2024
PRECISE Level 1 clinical trial sites activated, Launch of MagnetOs in Middle East countries
June 2024
MagnetOs Level 1 study published in Spine, MagnetOs Easypack Putty FDA cleared for standalone, extremities and pelvis
April 2024
MagnetOs Putty FDA cleared for interbody use
January 2024
MagnetOs Easypack Putty and MagnetOs Granules FDA cleared for interbody use, MagnetOs Putty FDA cleared for standalone use
November 2023
MagnetOs Flex Matrix FDA cleared for interbody use
October 2023
Chris Fair appointed CEO
August 2023
Sales distribution agreement with top 3 spine company announced
June 2023
US HQ moved to Atlanta
February 2022
MagnetOs Granules FDA cleared for standalone use
August 2021
US office opened in Boston
July 2021
First human data for MagnetOs published
July 2021
Launch of MagnetOs in nine European countries
July 2019
Signing of first APAC distributor
June 2018
First patient treated with MagnetOs (US)
February 2018
US Registration and virtual office established
January 2017
Acquired Xpand Biotechnology in 2017
to strengthen the biologics platform
May 2016
Listed on Swiss Exchange
March 2000
Founded as a spin-off of Swiss Federal Institute of Technology in Zurich
Nothing to display.
Nothing to display.